Heartflow, Inc. (HTFL) Form 8-K — Aug 13, 2026
Heartflow reported second quarter 2026 revenue of $64.1 million, up 48% year over year, with gross margin expanding to a record 83.0% from 75.5% in the prior-year period. U.S. revenue grew 51% to $59.6 million on higher FFRCT and Plaque Analysis case volumes. Net loss was $15.7 million, or $0.18 per share, while non-GAAP net loss narrowed sharply to $5.8 million ($0.07 per share) from $17.6 million ($2.79 per share) a year earlier, and Adjusted EBITDA improved to negative $6.7 million from negative $10.1 million.
Key figures
- Revenue
- 64100000
- Guidance
- FY2026 revenue of $246 million to $250 million (approximately 40% to 42% growth), raised from $228 million to $232 million (approximately 29% to 32% growth); non-GAAP gross margin of approximately 82%, up from approximately 81% previously
- Revenue Yoy
- 48%
- Cash Position
- 246800000
- Us Revenue
- 59600000
- Gross Margin
- 83.0% (vs 75.5% prior year)
- Gross Profit
- 53200000
- Total Assets
- 344463000
- Us Revenue Yoy
- 51%
- Adjusted EBITDA
- -$6.7 million (vs -$10.1 million prior year)
- Non Gaa PNet Loss
- $5.8 million, or ($0.07) per share (vs $17.6 million, or ($2.79), prior year)
- Patients Managed
- more than 750,000
- Net Operating Loss
- $17.9 million (vs $13.7 million prior year)
- Non Gaa PGross Margin
- 83.3%
- Institutions Adopted
- more than 1,800
- International Revenue
- 4500000
- Total Operating Expenses
- $71.1 million, or 111% of revenue
- Asset Impairment Charge H1
- $7.5 million
- International Revenue Yoy
- 12%
- Non Gaa PNet Operating Loss
- $7.9 million (vs $11.5 million prior year)
- Weighted Average Shares Q2
- 86398778
Price after filing
Close on the filing date to close N calendar days later (from $31.01). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.